linjc16/ctgov huggingface dataset:
Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect blood samples from pregnant women who achieved pregnancy following in-vitro fertilization (IVF) with Natera's preimplantation aneuploidy screening (with or without single gene gene testing). These samples will be used for test development of non-invasive prenatal diagnostic testing.

Detailed Description
-----------------
Eligible subjects will sign a consent form and have blood drawn at approximately 8-17 weeks gestation. Subjects will received $200 reimbursement for providing this blood sample. The collected samples will be used to help develop non-invasive prenatal diagnostic testing using Natera's Parental Support technology which is already commercialized for genetic diagnosis of in-vitro embryos. In this study, the technology will be tested for it's ability to analyze fetal-specific pieces of DNA isolated from the mother's blood. No results of the maternal blood testing will be reported to the subject or to their physicians.

Official Title
-----------------
Prenatal Diagnosis of Fetal DNA Isolated From Maternal Plasma

Conditions
-----------------
Pregnancy Following IVF With PGS/PGD

Intervention / Treatment
-----------------
* Procedure: Blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women willing to donate a blood sample during the first or second trimester of their pregnancy (approximately 8-17 weeks gestation) Use of Natera (formerly Gene Security Network)'s commercial preimplantation genetic testing (PGS/PGD)to achieve the current pregnancy Exclusion Criteria: Pregnant women who did not use Natera (formerly Gene Security Network)'s PGS/PGD testing to achieve their current pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant women<br>Women pregnant following the use of Natera's PGS/PGD testing | Procedure: Blood draw<br>* Maternal blood draw at approximately 8-17 weeks gestation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of 500 maternal blood samples to be used for development of non-invasive prenatal diagnostic testing. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Maternal Blood, PGD, PGS, Natera, Gene Security Network, Non-invasive prenatal diagnosis
Effects of Malnutrition on Colon Cancer Patients With Abdominal Surgery

Study Overview
=================
Brief Summary
-----------------
The prevalence of malnutrition in patients with colorectal cancer is recorded. We want to find out, if a malnourished patient has more complications after the elective surgery.

Detailed Description
-----------------
All patients attending elective colorectal surgery are screened for malnutrition in advance. Their length of stay in the hospital and the complications are recorded.

Official Title
-----------------
Effects of Malnutrition on Colon Cancer Patients With Abdominal Surgery

Conditions
-----------------
Malnutrition, Colon Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colorectal Carcinoma Elective surgery Informed consent Exclusion Criteria: Survival < 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All<br>All patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complication rate |  | during stay | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | during stay | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malnutrition, Colon cancer, Colon surgery, Outcome, Complication rate
Analysis of Cerebral Correlates of Pedophilia With Neuroimaging Techniques

Study Overview
=================
Brief Summary
-----------------
The main objective is to identify cerebral correlated of pedophilia using neuroimaging techniques.

Official Title
-----------------
Analysis of Cerebral Correlates of Pedophilia With Neuroimaging Techniques

Conditions
-----------------
Pedophilia

Intervention / Treatment
-----------------
* Behavioral: Pedophiles patients
* Behavioral: Healthy subjects
* Device: PET/MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (for patients): Diagnosis of pedophilia Male Age between 18 and 65 Informed consent signed Inclusion Criteria (for healthy patients): Male Age between 18 and 65 Informed consent signed Exclusion Criteria (for patients): IQ <70 Ongoing treatment with cyprostrerone acetate or GnRH agonist or antidepressant treatment (5HT reuptake inhibitor) Ongoing detention Exclusion Criteria (for healthy patients): psychiatric disorders IQ<70 Sexual disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Pedophiles patients<br>Adults diagnosed with pedophilia | Behavioral: Pedophiles patients<br>* cerebral MRI and/or cerebral PET imaging<br>Device: PET/MRI<br> <br> |
| Other: Healthy subjects<br>Healhy subjects (not diagnosed with pedophilia) | Behavioral: Healthy subjects<br>* cerebral MRI and/or cerebral PET imaging<br>Device: PET/MRI<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BOLD contrast signal | Assesment of physiological measurements by Magnetic resonance imaging (MRI) | 3 months | 
| Local cerebral blood flow | Assesment of physiological measurements by Positron Emission Tomography (PET) | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain, pedophilia, neuroimaging
Effects of Warm up in Athletes With Previous Hamstring Injury

Study Overview
=================
Brief Summary
-----------------
The objectives of this study is to determine the immediate and 10 minutes follow-up effects of a warm-up based on a continous run on a treadmill or the application of a hot-pack in athletes with previous hamstring injury. The investigators have as an hypothesis that the subjects, after one of this interventions show statistically significant improvements in the measurements of pain, flexibility, proprioception and postural control

Official Title
-----------------
Analysis on the Effects of Two Types of Warm up in Athletes With a Previous Hamstring Injury

Conditions
-----------------
Previous Hamstring Injury

Intervention / Treatment
-----------------
* Other: Warm Up
* Other: Hot Pack


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be 18-27 years old To do sports as a minimum of 5 hours per week. To have done sport in the last 2 years Have a hamstring flexibility of ≤80º on Kendall test Diagnosed hamstring injury the last year Exclusion Criteria: To take drugs that alter the motor o postural control To do a program of stretching of the hamstring To have lumbar pain Recent abdominal or spinal surgery intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 27 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Two groups. One realize an static warm-up and the other a dynamic warm-up.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Warm Up<br> | Other: Warm Up<br>* Run on a treadmill during 10 minutes without fatigue of the participant after this time.<br>|
| Active Comparator: Hot Pack<br> | Other: Hot Pack<br>* 20 minutes of hot-pack on both hamstring<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Range of movement | degrees | Changes from baseline at immediately after and at 10 minutes after the intervention | 
| Pain | Visual Analogue Scale. From 0 (not pain) to 10 (maximum pain in the world) | Changes from baseline at immediately after and at 10 minutes after the intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pressure pain threshold (PPT) | Measurement of the pressure (kg/cm2) with an algometer | Changes from baseline at immediately after and at 10 minutes after the intervention | 
| Joint Position Sense | Degrees | Changes from baseline at immediately after and at 10 minutes after the intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thermotherapy, warm-up, extensibility, pain, athletes
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

Study Overview
=================
Brief Summary
-----------------
Aim of the study is to determinate the frequency of acute renal failure in COVID-19 patients, its relationship with the severity of COVID-19 disease in ICU, and the ability to take precautions against these factors.

Official Title
-----------------
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

Conditions
-----------------
COVID19, Acute Renal Failure

Intervention / Treatment
-----------------
* Other: BRESCİA-COVİD Respiratory Severity Scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalized in the intensive care unit diagnosed with COVID-19 will include in the study. Exclusion Criteria: there is no exclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute Renal Failure in ICU<br>COVID-19 Patients with Acute Renal Failure in ICU | Other: BRESCİA-COVİD Respiratory Severity Scale<br>* KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| KDIGO criteria | KDIGO Criteria stage 1: Increase in SCr by ≥ 0.3 mg/dL within 48 hours or increase in SCr 1.5 to 1.9 times baseline which is known or presumed to have occurred within the prior 7 days Stage 2: 2.0 to 2.9 multiplied by baseline SCr; Stage 3: 3.0 or more multiplied by baseline; increase in SCr ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage. | 6 months | 
| BRESCIA-COVID RESPIRATORY SEVERITY SCALE (BCRSS) scores | The BCRSS score (between level 0-8) is calculated from www.mdcalc.com/brescia-covid-respiratory-severity-scale-bcrss-algorithm according to the severity of COVID disease , respiratory rate, PaO2 level, chest x-ray, and clinical status. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID19, Acute Renal Failure
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Study Overview
=================
Brief Summary
-----------------
Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes. Clomiphene citrate is a well known selective estrogen receptor modulator that increases gonadotropin secretion via hypothalamic-pituitary action. We conducted a prospective, open label clinical trial of CC to evaluate its effects in reverting persistent HH in male patients with prolactinomas under dopaminergic agonist treatment.

Official Title
-----------------
Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Conditions
-----------------
Hypogonadotropic Hypogonadism, Prolactinoma

Intervention / Treatment
-----------------
* Drug: Clomiphene citrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a minimum follow-up of 6 months under DA therapy with normal serum prolactin or with maximum DA dose (3.5 mg/week of cabergoline or 10 mg/day of bromocriptine for at least 2 months) serum total testosterone less than 300ng/dl with normal or low LH and FSH levels after discontinuing testosterone replacement for at least 2 months. Exclusion Criteria: impossibility to attend scheduled visits and irregular compliance to DA treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Clomiphene<br>Clomiphene 50 mg/day for 12 weeks | Drug: Clomiphene citrate<br>* Clomiphene 50 mg/day for 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assess the effects of CC treatment on testosterone levels in male patients with prolactinomas and persistent HH on dopaminergic agonist therapy |  | 10 days, 4, 8 and 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the effects of CC on sexual function, fertility, body composition, lipid and glucose metabolism, and quality of life were also evaluated. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypogonadotropic hypogonadism, Prolactinoma
Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare radiological behavior of blocks of macroporous phosphocalcium as bone substitute in comparison with iliac crest autograft in tibial valgus osteotomy.

Official Title
-----------------
Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy

Conditions
-----------------
Osteoarthritis of the Knee

Intervention / Treatment
-----------------
* Device: calcium phosphate macroporous bioceramics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: knee osteoarthritis eligible for tibial valgus osteotomy > 18 y.o Exclusion Criteria: prior tibial osteotomy history of local infection rheumatoid and other inflammatory arthritis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: calcium phosphate macroporous bioceramics|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiological healing and stability of the osteotomy measure at 3, 6, 12 and 24 months after surgery |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee and iliac crest painSurgical complicationsFonctional results |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Calcium phosphate ceramic, tibial osteotomy, osteoarthritis
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Japan. The aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (NovoSeven®) under normal clinical practice conditions.

Official Title
-----------------
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Conditions
-----------------
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Intervention / Treatment
-----------------
* Drug: eptacog alfa (activated)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with haemophilia A and B with inhibitors who received eptacog alpha (NovoSeven®) as treatment Exclusion Criteria: Patients who was not deemed to be appropriate to the treatment of eptacog alpha (NovoSeven®)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| eptacog alpha users<br> | Drug: eptacog alfa (activated)<br>* Prescription of eptacog alpha at the discretion of the physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of bleed treatments resulting in effective bleed resolution: Markedly effective, effective, moderate or ineffective |  | Year 1 | 
| Percentage of bleed treatments resulting in effective bleed resolution: Markedly effective, effective, moderate or ineffective |  | Year 10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adverse events (AEs), including serious adverse events (SAEs) |  | Baseline, every 1 year, Year 10 |
CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Study Overview
=================
Brief Summary
-----------------
The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.

Detailed Description
-----------------
Patients will be randomly assigned in 1:1 ratio either to candesartan (target dose 32 mg once daily) or matching placebo. The initial dose of the study drug will be 8 mg once daily. Study drug dose will be then doubled as tolerated every 2 weeks while aiming for a target dose of 32 mg once daily. Monitoring of blood pressure, serum creatinine, serum potassium and pressure gradient in LV outflow tract will be performed during dose increase. Patients will be observed clinically at 3, 6, and 12 months after the maintenance dose was reached. Exercise tolerance will be assessed by bicycle ergometry, presence of malignant arrhythmias by Holter monitoring, extent of LV hypertrophy by 2-dimensional echocardiography, and LV outflow tract pressure gradient by Doppler echocardiography at baseline and 12-month follow-up.

Official Title
-----------------
Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study

Conditions
-----------------
Hypertrophic Cardiomyopathy

Intervention / Treatment
-----------------
* Drug: candesartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HCM defined on the basis of echocardiographic criteria showing a nondilated, hypertrophied left ventricle (any wall thickness > 15 mm) in the absence of known causes of LV hypertrophy hypertension or valvular disease Exclusion Criteria: Hypertrophic obstructive cardiomyopathy defined as presence of resting gradient in left ventricular outflow tract ³30 mmHg or in righ ventricular outflow tract ³15 mmHg at Doppler echocardiography; Atrial fibrillation; Treatment with ACE inhibitors or AT1-R antagonists any time in the past; Contraindications to AT1-R antagonists; Coronary artery disease, renal failure, hepatic disorders or serious intercurrent illness limiting survival; and Poor echocardiographic image quality.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: candesartan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |